0001104659-24-086369.txt : 20240807 0001104659-24-086369.hdr.sgml : 20240807 20240806184446 ACCESSION NUMBER: 0001104659-24-086369 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240805 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240807 DATE AS OF CHANGE: 20240806 FILER: COMPANY DATA: COMPANY CONFORMED NAME: FENNEC PHARMACEUTICALS INC. CENTRAL INDEX KEY: 0001211583 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-32295 FILM NUMBER: 241180907 BUSINESS ADDRESS: STREET 1: PO BOX 13628 STREET 2: 68 TW ALEXANDER DRIVE CITY: RESEARCH TRIANGLE PARK STATE: NC ZIP: 27709 BUSINESS PHONE: (919) 636-4530 MAIL ADDRESS: STREET 1: PO BOX 13628 STREET 2: 68 TW ALEXANDER DRIVE CITY: RESEARCH TRIANGLE PARK STATE: NC ZIP: 27709 FORMER COMPANY: FORMER CONFORMED NAME: FENNEC PHARMACEUTICALS, INC. DATE OF NAME CHANGE: 20140903 FORMER COMPANY: FORMER CONFORMED NAME: ADHEREX TECHNOLOGIES INC DATE OF NAME CHANGE: 20021223 8-K 1 tm2421051d1_8k.htm FORM 8-K
false 0001211583 0001211583 2024-08-05 2024-08-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K

 

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 5, 2024

 

FENNEC PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

 

001-32295

(Commission File Number)

 

British Columbia, Canada   20-0442384

(State or other jurisdiction of

incorporation)

  (I.R.S. Employer Identification No.)

 

PO Box 13628, 68 TW Alexander Drive,

Research Triangle Park, NC

 

 

27709

(Address of principal executive offices)   (Zip Code)

  

Registrant’s telephone number, including area code: (919) 636-4530

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12 of the Act:

 

Title of each class Trading symbol(s) Name of each exchange on which 
registered
Common shares, no par value FENC Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On August 5, 2024, Fennec Pharmaceuticals Inc.’s (the "Company") announced the departure of Rostislav Raykov from his position as the Company’s Chief Executive Officer (“CEO”). Mr. Raykov has served as CEO and a member of the Company’s board of directors (“Board”) for 15 years. Mr. Raykov will remain a member of the Company’s Board.

 

In connection with Mr. Raykov’s departure as CEO, on August 5, 2024, the Company and Mr. Raykov entered into a Confidential Separation Agreement pursuant to which, among other terms customary for an agreement of this type, the Company agreed to accelerate the vesting of certain options held by Mr. Raykov to purchase up to 292,359 common shares of the Company at a weighted average price of $7.50. Mr. Raykov holds 148,609 restricted share units which shall remain in full force and effect and will vest in accordance with the original terms when awarded, such that all shares will be released from restriction by April 30, 2027.

 

On August 5, 2024, the Company announced the appointment of Jeffrey S. Hackman as CEO and a member of the Board. There are no arrangements or understandings between Mr. Hackman and any other person pursuant to which Mr. Hackman was appointed as CEO. Mr. Hackman has no family relationships with any other executive officer or director of the Company. Mr. Hackman has not been involved in any related person transactions with the Company that would require disclosure under Item 404(a) of Regulation S-K.

 

Mr. Hackman, age 62, brings more than 30 years of commercial leadership experience to the Company, including oversight of more than 10 product launches across a wide range of therapeutic areas and markets. His tenure in oncology spans the last 12 years across Sigma Tau, Baxalta, Shire, and EUSA Pharma, where he was responsible for the U.S. commercial organizations and managing respective product portfolios in multiple franchises, which generated billions in revenue over the years. More specifically, Mr. Hackman has successfully commercialized products that are specifically relevant to the PEDMARK® markets, including the outpatient oncology community and the AYA population.

 

In connection with Mr. Hackman’s appointment to CEO, he entered into an employment agreement with the Company effective as of August 5, 2024. Mr. Hackman’s employment agreement is an “at-will” agreement.

 

Pursuant to the terms of the employment agreement, Mr. Hackman’s initial base annualized salary will be at a rate of $550,000, subject to review and increase from time to time by the Company in its sole discretion. He shall be entitled to receive an annual target performance bonus (the “Target Bonus”) of fifty percent (50%) of Mr. Hackman’s base salary per 12-month period (which may be pro-rated for any partial period of less than 12 months), based upon a determination by the Board of the achievement of objectives to be set from time to time by the Board, provided that Mr. Hackman must remain employed through the payment date to be eligible to receive the Target Bonus. In addition, the Company will grant Mr. Hackman 400,000 options to purchase common shares of the Company which (i) have an exercise price per share equal to the “Fair Market Value” (as defined in Company’s 2020 Equity Incentive Plan); (ii) have a term of ten years and one-third of which shall vest one year after the date of the grant and the balance thereof shall vest monthly thereafter for two years in equal increments, and (iii) are otherwise subject to the terms and conditions set forth in the Company’s 2020 Equity Incentive Plan.

 

Mr. Hackman’s employment agreement generally provides that if his employment is terminated without “Cause” (as defined in the employment agreement) and other conditions are satisfied, then Mr. Hackman shall receive as severance an amount equal to his then current base salary for a period of twelve (12) months, less standard withholdings for tax and social security purposes.

 

The foregoing description of the Confidential Separation Agreement is qualified by the complete text of the Confidential Separation Agreement, a copy of which is attached at Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference herein. The foregoing description of the Executive Employment Agreement is qualified by the complete text of the Executive Employment Agreement, a copy of which is attached as Exhibit 10.2 to this Current Report on Form 8-K and is incorporated by reference herein.

 

 

 

 

Item 8.01 Other Items.

 

On August 5, 2024, the Company issued a press release announcing Mr. Raykov’s departure as the Company’s CEO and Mr. Hackman’s appointment as CEO and a member of the Board. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information contained in this Item 8.01, including the press release attached hereto, is being furnished and shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, unless such subsequent filing specifically references this Form 8-K.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No. Description
   
Exhibit 99.1 Press Release dated August 5, 2024
Exhibit 10.1 Confidential Separation Agreement between the Company and Rostislav Raykov, effective as of August 5, 2024
Exhibit 10.2 Executive Employment Agreement between the Company and Jeffrey S. Hackman, effective as of August 5, 2024
104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    FENNEC PHARMACEUTICALS INC.
     
     
Date August 6, 2024 By: /s/ Robert Andrade
    Robert Andrade
Chief Financial Officer

 

 

 

EX-10.1 2 tm2421051d1_ex10-1.htm EXHIBIT 10.1

Exhibit 10.1

 

CONFIDENTIAL SEPARATION AGREEMENT

 

THIS CONFIDENTIAL SEPARATION AGREEMENT (the “Agreement”) is made and entered into on August ___, 2024 by and among Rostislav Raykov (the “Executive”) and Fennec Pharmaceuticals, Inc., a Delaware corporation (“Fennec US”), Fennec Pharmaceuticals Inc., a British Columbia corporation (“Parent”) (Fennec US, Parent and their respective affiliated corporations, predecessors, and successors are collectively referred to herein as the “Company”). The Executive and the Company are sometimes referred to collectively as the “Parties” and individually as a “Party”.

 

RECITALS

 

WHEREAS, the Executive is employed by Fennec US pursuant to an employment agreement dated May 3, 2010 (the “Employment Agreement”);

 

AND WHEREAS the Company and the Executive mutually wish for Executive’s employment with the Company to cease effective on the close of business on August 4th, 2024 (the “Effective Date”);

 

AND WHEREAS, the Parties wish to confirm their respective rights and obligations in connection with the foregoing cessation of the Executive’s employment with the Company.

 

AGREEMENT

 

NOW THEREFORE, in consideration of and in exchange for the promises and covenants contained in this Agreement and the valuable consideration described herein, the sufficiency of which is hereby acknowledged by the Parties, the Parties mutually agree as follows:

 

1.             Separation Arrangements

 

(a)           Cessation of Employment. Executive and Company hereby agree and confirm that Executive’s employment shall end effective as of the Effective Date. Executive hereby agrees to resign as Chief Executive Officer (as well as any other officer position with any Company entity) on the day following the certification and filing of the Parent’s consolidated interim financial statements for the period ended June 30, 2024.

 

(b)           Continuation as Board Member. Notwithstanding clause (a) of this Section 1, the Parties agree that Executive shall not be resigning from the board of directors of Parent (the “Board”).

 

(c)          Remuneration and Vacation Up to Effective Date. The Company shall pay to the Executive his normal salary, less usual deductions for federal, state and local payroll taxes and other withholdings, up to and including the Effective Date in accordance with the Company’s normal payroll procedures. The pro rata portion of the Executive’s annual vacation entitlement that has not been taken prior to the Effective Date shall also be paid in accordance with the Company’s normal payroll procedures.

 

(d)            Expense Reimbursement. Executive will be reimbursed for all customary, ordinary and necessary business expenses incurred by Executive in the performance of Executive’s duties up to the Effective Date, all in accordance with the Employment Agreement and Company policies, provided Executive furnishes the Company with vouchers, receipts and other details of such expenses prior to the date that is ninety (90) days after the Effective Date.

 

(e)            Additional Payments. The Company shall also pay to Executive:

 

(i)         an amount equal to Executive’s current Base Salary, less usual deductions for federal, state and local payroll taxes and other withholdings, for a period of one (1) year, which amount shall be paid within five (5) days of the Effective Date; and

 

(ii)        a pro rata share of the Executive’s Annual Bonus (but only to the extent actually earned by Executive) not paid prior to the Effective Date, which shall be paid, less usual deductions for federal, state and local payroll taxes and other withholdings, after the 2024 fiscal year in accordance with the Company’s usual practice.

 

 

 

 

(f)            Options/RSUs. The Parties acknowledge and confirm that, as of the Effective Date, the Executive will, assuming no intervening exercises between now and then, hold the options and restricted stock units set forth in Schedule “A”. By remaining on the Board, the Parties confirm that the Executive remains a “Participant”, as such term is defined in the Parent’s Amended and Restated Stock Option Plan (the “Original Plan”), and in a “Service Relationship” as such term is defined in Parent’s 2020 Equity Incentive Plan (the “2020 Plan”). Accordingly, the options and RSUs set forth in Schedule “A” shall not be terminated in connection with the Executive’s change in status from an employee to a Board member and shall remain in in full force and effect in accordance with their respective terms and the Company plan under which they were granted (i.e. either Original Plan or the 2020 Plan, as applicable).

 

(g)           Vesting / Exercise Period. The Company agrees to accelerate the vesting of all options set forth in Schedule “A” which by their terms have not vested as of the Effective Date. The RSUs shall vest in accordance with their original terms. All options set forth in Schedule “A” shall remain exercisable until the earliest of: (i) their original respective date of expiry (as set forth in the column entitled Original Expiry Date, where applicable); (ii) the third anniversary of the date on which Executive no longer serves on the Board and is otherwise no longer a Participant or in a Service Relationship with the Company; or (iii) termination in connection with a Change in Control (as such term is defined in the Original Plan) or a Sale Event (as such term is defined in the 2020 Plan), as applicable.

 

(h)            COBRA Benefits. Executive’s existing coverage under the Company’s group health plan (and, if applicable, the existing group health coverage for his or her eligible dependents) will end on the last day of August, 2024. Executive and his or her eligible dependents may then be eligible to elect temporary continuation coverage under the Company’s group health plan in accordance with the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”). Executive and his eligible dependents has been provided with a COBRA election form and notice which describe his rights to continuation coverage under COBRA. If Executive timely elects COBRA continuation coverage, then the Company will pay for COBRA coverage for him and, if applicable, his eligible dependents until the earliest of (i) the date that is twelve months after the Effective Date; (ii) the date when the Executive becomes eligible for health insurance coverage in connection with new employment or self-employment; or (iii) the date the Executive ceases to be eligible for COBRA continuation coverage for any reason.

 

(i)            Other Benefits. Other than as specifically provided above in this Section 1, Executive’s participation in any and all other Company employee benefit plans (including without limitation under the Parent’s Management M&A Incentive Plan dated November 15, 2022, as amended (the “M&A Incentive Plan”)) shall cease on the Effective Date. The Executive hereby consents to the termination of the M&A Incentive Plan. Further, in consideration of the benefits provided to the Executive under this Section 1, Executive agrees that he will not be granted any additional options or receive any additional cash fees for serving on the Board until the next annual election of directors.

 

(j)             Release. The consideration provided to Executive in clauses (e), (f), (g) and (h) of this Section 1 are conditional upon Executive signing and delivering this Agreement and not revoking the Release, as defined in Section 2 below.

 

2.             Acknowledgements and Release

 

(a)           Acknowledgements. The Executive acknowledges and agrees that he does not have any right to: (i) receive any cash payments from the Company other than as set forth in clauses (c), (d), (e) and (h) of Section 1 above; (ii) receive, acquire, possess, or vest into any additional stock options, shares, or restricted stock units, or any other shares, warrants, securities, derivative securities, or other class of capital stock of the Company other than as set forth in clause (f) and (g) of Section 1 above; or (iii) receive any other benefits other than as set forth in clause (h) of Section 1. The Executive hereby also acknowledges that he fully understands the terms of this Agreement, and has had the opportunity to receive independent legal representation in connection with the entering into this Agreement, and voluntarily accepts the payments and other benefits herein in consideration for the release set forth in subsection 2(b) below (the “Release”).

 

 

 

 

(b)           Release. The Executive, for himself or anyone who may have a claim by or through him, and for his heirs, estate, executors, administrators, successors and assigns, hereby releases, acquits and forever discharges the Company, as well as each of the Company’s respective affiliates, parents, subsidiaries and related entities, officers, directors, shareholders, members, employees (past and present), professional employer organizations, as well as the Company’s insurers, reinsurers, agents, servants, representatives, attorneys, and assigns, and any and all other entities with whom the Company has been, are now, or may hereafter be affiliated (collectively “Releasees”), from any and all claims, demands, obligations, actions, causes of action, liabilities, debts, promises, agreements, demands, attorneys’ fees, losses and expenses, known or unknown, suspected or unsuspected, filed or unfiled, that Executive may have or have had arising out of any known or unknown fact, condition or incident occurring prior to the date of this Agreement, including but not limited to those arising out of or in connection with Executive’s employment, the cessation thereof, or any other interaction or relations with Releasees relating to the Company.

 

(c)           Understanding Respecting Release. It is understood and agreed that: (i) both the Release and any consideration transferred hereunder are deemed to be no admission whatsoever of liability on the part of the Releasees; and (ii) the Release shall not apply to the Company’s obligations set forth in this Agreement, nor to the Executive’s continued right to indemnification as an officer and/or director of any Company entity up to the Effective Date, including any actions taken in such positions up to the Effective Date, nor to the Executive’s continued right to indemnification as a director of Parent after the Effective Date, all as provided in Company constating documents and associated director and officer insurance policies of the Company; (iii) the Release shall enure to the benefit of the Releasees and shall be binding on the Executive as well as the Executive’s heirs, representatives, successors and assigns; and (iv) the Release is not a condition for the Executive to receive any money to which the Executive would otherwise be entitled to by operation of statute.

 

3.             No Representations Regarding Tax Consequences. The Executive understands and agrees that he (and not any Releasee) is solely responsible for payment of any taxes which are required to be paid to any governmental entity as a result of the Executive’s receipt of any of the consideration set forth in this Agreement, including but not limited to: (i) the options referred to in clauses (f) and (g) of Section 1, and the exercise thereof; and (ii) the RSUs referred to in clauses (f) and (g) of Section 1, and the vesting thereof.

 

4.             Continuing Obligations. Executive acknowledges and agrees that certain of Executive’s obligations under the Proprietary Information and Inventions Agreement signed by him continue after the Effective Date. These obligations include, but may not be limited to, obligations of confidentiality and obligations relating to any intellectual property to which Executive may have contributed while employed by the Company. Executive also acknowledges his continuing fiduciary obligations as a member of the Board. The Parties agree that, if a Sale Event has not occurred and, despite Executive remaining willing and able to serve on the Board, the Executive is not re-elected to the Board at the next annual meeting of shareholders, the Company may retain the Executive as an independent consultant. Any services provided by the Executive, and any remuneration therefor, under such independent consulting agreement shall be on a project-by-project basis, as may be agreed between the parties thereto at the time.

 

5.             Miscellaneous. This Agreement shall be interpreted under the laws of North Carolina, both as to interpretation and performance. This Agreement constitutes the entire agreement between the Parties regarding the Executive’s resignation and the cessation of Executive’s employment with the Company and supersedes all prior agreements, written or oral, between the Company and the Executive regarding such resignation and cessation of employment, and no other agreement, statement, or promise made by one Party to another as to any matter addressed in this Agreement shall be binding or valid. This Agreement cannot be orally modified. Any amendment or modification to this Agreement must be in writing, signed by the Executive and by a duly authorized representative of the Company. This Agreement, and all the terms and provisions contained herein, shall bind the heirs, personal representatives, successors and assigns of each Party, and inure to the benefit of each Party, its agents, directors, officers, employees, servants, successors, and assigns. This Agreement is the product of arms-length negotiations and is considered to be jointly drafted. As such, it shall not be construed against any Party because that Party caused it to be reduced to a written instrument. The Parties agree that the terms of this Agreement are fair, reasonable and adequate and the Parties covenant never to challenge this Agreement. The failure of any Party to insist upon compliance with any term, covenant or condition contained in this Agreement shall not be deemed a waiver of that term, covenant or condition, nor shall any waiver or relinquishment of any right or power contained in this Agreement at any one time or more times be deemed a waiver or relinquishment of any right or power at any other time or times. This Agreement may be executed in any number of counterparts, each of which will be deemed to be an executed Agreement and each of which shall be deemed to be one and the same instrument. A facsimile or digital signature shall be treated as an original signature for all purposes.

 

 

 

 

AGREED as of the date first written above.

 

   
  /s/ Rostislav Raykov
   
   
  FENNEC PHARMACEUTICALS, INc.
   
   
  By:                         
    /s/ Khalid Islam
   
   
  FENNEC PHARMACEUTICALS INC.
   
    
  By:  
    /s/ Khalid Islam

 

 

 

EX-10.2 3 tm2421051d1_ex10-2.htm EXHIBIT 10.2

Exhibit 10.2

 

EXECUTIVE EMPLOYMENT AGREEMENT

 

THIS EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is entered into the 5th day of August, 2024 by and between FENNEC PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and JEFF HACKMAN (the “Executive”).

 

WHEREAS the Company desires to employ the Executive in the capacity of full-time Chief Executive Officer pursuant to the terms of this Agreement and, in connection therewith, to compensate the Executive for Executive’s personal services to the Company;

 

AND WHEREAS the Executive wishes to be employed by the Company and provide personal services to the Company in return for certain compensation.

 

NOW THEREFORE, in consideration of the mutual promises and covenants contained herein, the parties agree to the following:

 

1.             EMPLOYMENT BY THE COMPANY.

 

1.1          At-Will Employment. Executive shall be employed by the Company on an “at-will” basis, meaning either the Company or Executive may terminate Executive’s employment at any time, with or without cause or advanced notice.  Any contrary representations that may have been made to Executive shall be superseded by this Agreement.  This Agreement shall constitute the full and complete agreement between Executive and the Company on the “at-will” nature of Executive’s employment with the Company, which may be changed only in an express written agreement signed by Executive and a duly authorized officer of the Company. Executive’s rights to any compensation following a termination shall be only as set forth in Section 6.

 

1.2          Position.  Subject to the terms set forth herein:

 

(i)             the Company agrees to employ Executive, and Employee hereby accepts such employment, commencing on August 5, 2024 (the “Start Date”); and

 

(ii)            the Company shall appoint Executive as the Chief Executive Officer and as member of the board of directors, and Executive hereby accepts such appointments, effective as of the day following the certification and filing of the consolidated interim financial statements of the Company’s parent, Fennec Pharmaceuticals Inc., a British Columbia corporation (the “Parent”), for the period ended June 30, 2024.

 

During the term of Executive’s employment with the Company, Executive will devote Executive’s best efforts and substantially all of Executive’s business time and attention to the business of the Company. Executive will also be appointed Chief Executive Officer and member of the Board of Directors (the “Board”) of the Parent effective on the date referred to in subsection 1.2(ii) above

 

1.3          Duties.  Executive will report to the Board, performing such duties as are normally associated with his position and such duties as are assigned to him from time to time, subject to the oversight and direction of the Board, or the Compensation Committee thereof.  Executive shall perform his duties under this Agreement principally out of Boston Metro Area.  In addition, the Executive shall make such business trips to such places as may be necessary or advisable for the efficient operations of the Company.

 

1.4          Company Policies and Benefits.  The employment relationship between the parties shall also be subject to the Company’s personnel policies and procedures as they may be interpreted, adopted, revised or deleted from time to time in the Company’s sole discretion.  The Executive will be eligible to participate on the same basis as similarly situated employees in the Company’s benefit plans in effect from time to time during his employment.  All matters of eligibility for coverage or benefits under any benefit plan shall be determined in accordance with the provisions of such plan.  The Company reserves the right to change, alter, or terminate any benefit plan in its sole discretion.  Notwithstanding the foregoing, in the event that the terms of this Agreement differ from or are in conflict with the Company’s general employment policies or practices, this Agreement shall control.

 

1.5          Paid Time Off.  The Executive will be eligible for up to twenty (20) days of paid time off per calendar year in accordance with any paid leave policy adopted by the Company from time to time.

 

 

 

 

2.             COMPENSATION.

 

2.1          Salary.  Executive shall receive for Executive’s services to be rendered hereunder an initial annualized base salary of US$550,000 per year, subject to review and increase from time to time by the Company in its sole discretion, payable subject to standard federal and state payroll withholding requirements in accordance with Company’s standard payroll practices (“Base Salary”).

 

2.2          Bonus.

 

(a)           During Employment. Executive shall be eligible to earn an annual target performance bonus of 50% of his Base Salary (“Annual Bonus”).  The Annual Bonus, which may be more or less than the target Annual Bonus will be based upon the assessment of the Executive’s performance by the Board and the Company’s attainment of targeted goals as set by the Board in its discretion after consultation with Executive.  The Annual Bonus, if any, will be subject to applicable payroll deductions and withholdings.  Following the close of each calendar year, the Board will determine whether the Executive has earned the Annual Bonus, and the amount of any Annual Bonus, based on the set criteria.  No amount of the Annual Bonus is guaranteed, and except as provided in Sections 6.1 and 6.4 below, the Executive must be an employee in good standing on the Annual Bonus payment date to be eligible to receive an Annual Bonus; no partial or prorated bonuses will be provided.  The Annual Bonus, if earned, will be paid no later than March 15th of the calendar year immediately following the applicable calendar year for which the Annual Bonus is being measured. 

 

(b)           Upon Termination.  Except as provided in Sections 6.1 and 6.4 below, in the event Executive leaves the employ of the Company for any reason prior to payment of any bonus, he is not eligible for such bonus, prorated or otherwise.

 

2.3          Stock Options.

 

(a)           Option Grant.  Executive will be granted options to purchase 400,000 common shares in the capital of the Parent (subject to adjustment for stock splits, dividends and combinations and similar events as will be set forth in the option agreement), with a 10-year term, pursuant and subject to the Parent’s 2020 Equity Incentive Plan (“Plan”) and the Parent’s standard form of Stock Option Agreement (“Stock Agreement’) between the Executive and the Parent (the “Option”).   The Option will have an exercise price per share equal to the fair market value of a common share in the capital of the Parent, to be determined in accordance with the Plan.

 

(b)          Vesting.  The Option shall vest over a period of three years as follows: (i) 33 1/3%% of the total shares subject to the Option shall vest on the first anniversary of the Start Date, and (ii) 1/24th of total shares subject to the Option shall vest monthly thereafter over the remaining two years of the vesting period, subject to Executive’s continuous service as of each applicable date. 

 

2.4          Expense Reimbursement.  The Company will reimburse Executive for all reasonable, documented business expenses incurred in connection with his services hereunder, in accordance with the Company’s business expense reimbursement policies and procedures as may be in effect from time to time. In addition, the Company shall pay up to $5,000 of the reasonable attorney’s fees incurred by Executive in connection with the negotiation and documentation of this Agreement and any related agreements.

 

2.5          Indemnification. The Executive shall be entitled to indemnification to the maximum extent permitted by applicable law and the Company’s bylaws with terms no less favorable than provided to any other Company executive officer.  At all times during the Executive’s employment, the Company shall maintain in effect a directors and officers liability insurance policy with the Executive as a covered officer.

 

3.             PROPRIETARY INFORMATION AND INVENTIONS ASSIGNMENT AGREEMENT.  The parties hereto have entered into a Proprietary Information and Inventions Assignment Agreement (the “Proprietary Information Agreement”), which may be amended by the parties from time to time without regard to this Agreement.  The Proprietary Information Agreement contains provisions that are intended by the parties to survive and do survive termination or expiration of this Agreement.

 

4.             OUTSIDE ACTIVITIES.  Except with the prior written consent of the Company’s Board, Executive will not, while employed by the Company, undertake or engage in any other employment, occupation or business enterprise that would interfere with Executive’s responsibilities and the performance of Executive’s duties hereunder except for (i) reasonable time devoted to volunteer services for or on behalf of such religious, educational, non-profit and/or other charitable organization as Executive may wish to serve; (ii) reasonable time devoted to activities in the non-profit and business communities consistent with Executive’s duties; (iii) reasonable time devoted to service on boards of directors of companies that are not competitive with the Company, do not otherwise present a conflict of interest and would not otherwise interfere with Executive’s responsibilities and the performance of Executive’s duties hereunder, subject to the prior written approval of the Board (which approval shall not be unreasonably withheld); and (iv) such other activities that would not interfere with Executive’s responsibilities and the performance of Executive’s duties hereunder as may be specifically approved by the Board (which approval shall not be unreasonably withheld).  This restriction shall not, however, preclude the Executive from owning less than one percent (1%) of the total outstanding shares of a publicly traded company.

 

5.             NO CONFLICT WITH EXISTING OBLIGATIONS.  Executive represents that Executive’s performance of all the terms of this Agreement and as an employee of the Company do not and will not breach any agreement or obligation of any kind made prior to Executive’s employment by the Company, including agreements or obligations Executive may have with prior employers or entities for which Executive has provided services.  Executive has not entered into, and Executive agrees that Executive will not enter into, any agreement or obligation, either written or oral, in conflict herewith.

 

 

 

 

6.             TERMINATION OF EMPLOYMENT.  The parties acknowledge that Executive’s employment relationship with the Company is at-will.  Either Executive or the Company may terminate the employment relationship at any time, with or without Cause.  The provisions in this Section govern the amount of compensation, if any, to be provided to Executive upon termination of employment and do not alter this at-will status.

 

6.1          Termination by the Company Without Cause.

 

(a)            The Company shall have the right to terminate Executive’s employment with the Company pursuant to this Section 6.1 at any time without “Cause” (as defined in Section 6.2(a) below) by giving notice as described in Section 6.6 of this Agreement.  A termination pursuant to Section 6.4 below is not a termination without “Cause” for purposes of receiving the benefits described in this Section 6.1.

 

(b)           Except as otherwise provided in this Section 6.1, upon termination of this Agreement for any reason, Executive shall not be entitled to any form of severance benefits, including benefits otherwise payable under any of Company’s regular severance plans or policies, or any other payment whatsoever. Executive agrees that (i) the payment of any severance or other benefits pursuant to this Section 6.1 shall be contingent on the delivery by Executive to Company of a release and waiver of legal claims related to the employment relationship between Executive and Company in a form reasonably acceptable to Company (the “Release”) and (ii) the payments and benefits provided hereunder, subject to the terms and conditions hereof, shall be in full satisfaction of any rights which he might otherwise have or claim by operation of law, by implied contract or otherwise. When the Release becomes effective and may no longer be revoked by the Executive (the “Release Date”), then:

 

(i)             the Company shall pay to Executive an amount equal to Executive’s then current Base Salary for a period of twelve (12) months (the “Severance Period”), less applicable withholdings and deductions (such twelve (12) months of Base Salary, less applicable withholdings and deductions, the “Severance Payment”), in installments in accordance with the Company’s ordinary payroll practices commencing on the Company’s first regular payroll date that is more than sixty (60) days following the Separation Date (as defined below), and shall be for any accrued Base Salary for the sixty (60) day period plus the period from the sixtieth (60th) day until the regular payroll date, if applicable, and all salary continuation payments thereafter, if any, shall be made on the Company’s regular payroll dates, until such time as the Severance Payment is paid in full.

 

(ii)            if the Separation Date occurs after the end of the prior fiscal year of the Company and before the payment date for the Annual Bonus relating to that fiscal year, the Company shall pay to Executive such Annual Bonus, to the extent earned, on the same date as annual bonuses for the fiscal year are paid to other senior executives of the Company (the “Prior Year Annual Bonus”).

 

(iii)           if the Executive timely elects continued coverage under COBRA for himself and his covered dependents under the Company’s group health plans following such termination, then the Executive will be entitled to the following COBRA benefits (the “COBRA Benefits,” together with the Severance Payment and the Prior Year Annual Bonus (to the extent earned), the “Severance Benefits”):  the Company shall pay the COBRA premiums necessary to continue the Executive’s and his covered dependents’ health insurance coverage in effect for himself (and his covered dependents) on the termination date until the earliest of (x) a number of months following the termination date equal to the Severance Period (the “COBRA Severance Period”); (y) the date when the Executive becomes eligible for health insurance coverage in connection with new employment or self-employment; or (iii) the date the Executive ceases to be eligible for COBRA continuation coverage for any reason, including plan termination (such period from the termination date through the earlier of (i)-(iii), the “COBRA Payment Period”).  Notwithstanding the foregoing, if at any time the Company determines that its payment of COBRA premiums on the Executive’s behalf would result in a violation of applicable law, then in lieu of paying COBRA premiums pursuant to this Section, the Company shall pay the Executive on the last day of each remaining month of the COBRA Payment Period, a fully taxable cash payment equal to the COBRA premium for such month, subject to applicable tax withholding (such amount, the “Special Severance Payment”), such Special Severance Payment to be made without regard to the Executive’s payment of COBRA premiums and without regard to the expiration of the COBRA period prior to the end of the COBRA Payment Period.  Nothing in this Agreement shall deprive the Executive of his rights under COBRA or ERISA for benefits under plans and policies arising under his employment by the Company.

 

(c)           Executive shall not receive the Severance Benefits pursuant to Section 6.1(b) unless he executes the Release within the consideration period specified therein, which shall in no event be more than sixty (60) days, and until the Release becomes effective and can no longer be revoked by Executive under its terms.  Executive’s ability to receive benefits pursuant to Section 6.1(b) is further conditioned upon his:  (i) returning all Company property; (ii) complying with his post-termination obligations under this Agreement and the Proprietary Information Agreement; and (iii) complying with the Release including, without limitation, customary non-disparagement and confidentiality provisions contained therein.

 

(d)           The benefits provided to Executive pursuant to this Section 6.1 are in lieu of, and not in addition to, any benefits to which Executive may otherwise be entitled under any Company severance plan, policy or program.

 

 

 

 

(e)           The damages caused by the termination of Executive’s employment without Cause would be difficult to ascertain; therefore, the severance for which Executive is eligible pursuant to Section 6.1(b) above in exchange for the Release is agreed to by the parties as liquidated damages, to serve as full compensation, and not a penalty.

 

6.2          Termination by the Company for Cause.  Subject to Section 6.2(b) below, the Company shall have the right to terminate Executive’s employment with the Company at any time for Cause by giving notice as described in this Section 6.2 and in Section 6.5 of this Agreement.

 

(a)           “Cause” for termination shall mean the occurrence of any of the following: (i) Executive’s conviction of any felony or any crime involving fraud or dishonesty; (ii) Executive’s participation in a fraud, act of dishonesty or other act of gross misconduct that adversely affects the Company; (iii) conduct by Executive that demonstrates Executive’s gross unfitness to serve under circumstances that materially and adversely affect the Company; (iv) Executive’s violation of any statutory or fiduciary duty, or duty of loyalty, owed to the Company; (v) Executive’s material breach of any material term of any contract between such Executive and the Company; and/or (vi) Executive’s serious violation of a material Company policy. Prior to termination for Cause pursuant to each event listed in (iii) and (iv) above, the Company shall give the Executive notice of such event(s), which notice shall specify in reasonable detail the circumstances constituting Cause, and an opportunity to explain the circumstances.  Prior to any termination for Cause pursuant to each event listed in (v) and (vi) above, to the extent such event(s) is (are) capable of being cured by Executive, (A) the Company shall give the Executive notice of such event(s), which notice shall specify in reasonable detail the circumstances constituting Cause, and an opportunity to cure, and (B) there shall be no Cause with respect to any such event(s) if the Board determines in good faith that such events have been cured by Executive within fifteen (15) days after the delivery of such notice.

 

(b)           In the event Executive’s employment is terminated at any time for Cause, Executive will not receive the Severance Benefits described in Section 6.1(b), or any other severance compensation or benefit, except that, pursuant to the Company’s standard payroll policies, the Company shall pay to Executive the accrued but unpaid salary of Executive through the date of termination and unreimbursed business expenses, together with all compensation and benefits payable to Executive based on his participation in any compensation or benefit plan, program or arrangement through the date of termination.

 

6.3          Resignation by the Executive.

 

(a)           Executive may resign from Executive’s employment with the Company at any time by giving notice as described in Section 6.5.

 

(b)           In the event Executive resigns from Executive’s employment with the Company, Executive will not receive the Severance Benefits, or any other severance compensation or benefit, except that, pursuant to the Company’s standard payroll policies, the Company shall pay to Executive the accrued but unpaid salary of Executive through the date of resignation, any unreimbursed business expenses, together with all compensation and benefits payable to Executive through the date of resignation under any compensation or benefit plan, program or arrangement during such period and Executive shall be eligible for any benefit continuation or conversion rights provided by the provisions of a benefit plan or by law.

 

6.4          Termination by Virtue of Death or Disability of the Executive.

 

(a)           In the event of Executive’s death while employed pursuant to this Agreement, all obligations of the parties hereunder shall terminate immediately, and the Company shall, pursuant to the Company’s standard payroll policies, pay to the Executive’s legal representatives Executive’s accrued but unpaid salary through the date of death, the unreimbursed business expenses, together with all compensation and benefits payable to Executive based on his participation in any compensation or benefit plan, program or arrangement through the date of termination. In addition, the Company shall pay to the Executive’s legal representatives the Prior Year Annual Bonus, to the extent earned.

 

(b)           Subject to applicable state and federal law, the Company shall at all times have the right, upon written notice to the Executive, to terminate this Agreement based on the Executive’s Disability (as defined below).  Termination by the Company of the Executive’s employment based on “Disability” shall mean termination because the Executive is unable due to a physical or mental condition to perform the essential functions of his position with or without reasonable accommodation for six (6) months in the aggregate during any twelve (12) month period or based on the written certification by a licensed physician of the likely continuation of such condition for such period.  This definition shall be interpreted and applied consistent with the Americans with Disabilities Act, the Family and Medical Leave Act, and other applicable law. In the event Executive’s employment is terminated based on the Executive’s Disability, Executive will not receive the Severance Benefits, or any other severance compensation or benefit, except that, pursuant to the Company’s standard payroll policies, the Company shall pay to Executive the accrued but unpaid salary of Executive through the date of termination, unreimbursed business expenses, together with all compensation and benefits payable to Executive based on his participation in any compensation or benefit plan, program or arrangement through the date of termination. In addition, the Company shall pay to Executive the Prior Year Annual Bonus, to the extent earned.

 

 

 

 

6.5          Notice; Effective Date of Termination.

 

(a)           Termination of Executive’s employment (the “Separation Date”) pursuant to this Agreement shall be effective as follows:

 

(i)             ten (10) days after the Company has provided Executive with written notice of Executive’s termination without Cause under Section 6.1;

 

(ii)            for a termination for Cause:  (1) under Section 6.2(a)(i) or (ii), immediately upon provision by the Company of written notice of the reasons to Executive; (2) under Section 6.2(a)(iii) or (iv), following the required written notice to Executive and expiration of the period during which Executive may explain; (3) under Section 6.2(a)(v) or (vi),  following the required written notice to Executive and expiration of the 15-day cure period, if Executive has not cured;

 

(iii)           immediately upon the Executive’s death;

 

(iv)          thirty (30) days after the Company gives notice to Executive of Executive’s termination on account of Executive’s Disability under Section 6.4, unless the Company specifies a later Separation Date, in which case, termination shall be effective as of such later Separation Date, provided that Executive has not returned to the full time performance of Executive’s duties prior to such date;

 

(v)           thirty (30) days after the Executive gives written notice to the Company of Executive’s resignation, provided that the Company may set a Separation Date at any time between the date of notice and the date of resignation, in which case the Executive’s resignation shall be effective as of such other date. 

 

Executive will receive compensation through the Separation Date.

 

(b)           In the event of a termination for Cause, written confirmation shall specify the subsection(s) of the definition of Cause relied on to support the decision to terminate.

 

6.6          Cooperation With Company After Termination of Employment. Following termination of Executive’s employment for any reason, Executive shall reasonably cooperate with the Company in all matters relating to the winding up of Executive’s pending work including, but not limited to, any litigation in which the Company is involved, and the orderly transfer of any such pending work to such other Executives as may be designated by the Company. The Company shall reimburse Executive for any reasonable expenses incurred by him in connection with providing such cooperation.

 

6.7          Section 409A.  It is intended that all payments and benefits under this Agreement shall either comply with or be exempt from the requirements of Section 409A of the Internal Revenue Code of 1986, as amended (“Code”), and any ambiguity contained herein shall be interpreted in such manner so as to avoid adverse personal tax consequences under Section 409A. Notwithstanding the foregoing, the Company shall in no event be obligated to indemnify the Executive for any taxes or interest that may be assessed by the Internal Revenue Service pursuant to Section 409A of the Code to payments made pursuant to this Agreement.

 

7.             GENERAL PROVISIONS.

 

7.1          Notices.  Any notices required hereunder to be in writing shall be deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by electronic mail, telex or confirmed facsimile if sent during normal business hours of the recipient, and if not, then on the next business day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt.  All communications shall be sent to the Company at its primary office location and to Executive at Executive’s address as listed on the Company payroll, or at such other address as the Company or the Executive may designate by ten (10) days advance written notice to the other.

 

7.2          Severability.  Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provisions had never been contained herein.

 

7.3          Waiver.  If either party should waive any breach of any provisions of this Agreement, such party shall not thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement.

 

7.4          Entire Agreement.  This Agreement constitutes the entire agreement between Executive and the Company with regard to the subject matter hereof.  This Agreement is the complete, final, and exclusive embodiment of their agreement with regard to this subject matter and supersedes any prior oral discussions or written communications and agreements.  This Agreement is entered into without reliance on any promise or representation other than those expressly contained herein, and it cannot be modified or amended except in writing signed by Executive and an authorized officer of the Company.  The parties have entered into a separate Proprietary Information Agreement and have or may enter into separate agreement related to stock option awards.  These separate agreements govern other aspects of the relationship between the parties, have or may have provisions that survive termination of the Executive’s employment under this Agreement, may be amended or superseded by the parties without regard to this Agreement and are enforceable according to their terms without regard to the enforcement provision of this Agreement.

 

 

 

 

7.5          Headings.  The headings of the sections hereof are inserted for convenience only and shall not be deemed to constitute a part hereof nor to affect the meaning thereof.

 

7.6          Successors and Assigns.  The Company shall assign this Agreement and its rights and obligations hereunder in whole, but not in part, to any Company or other entity with or into which the Company may hereafter merge or consolidate or to which the Company may transfer all or substantially all of its assets, if in any such case said Company or other entity shall by operation of law or expressly in writing assume all obligations of the Company hereunder as fully as if it had been originally made a party hereto, but may not otherwise assign this Agreement or its rights and obligations hereunder.  The Executive may not assign or transfer this Agreement or any rights or obligations hereunder, other than to his estate upon his death.

 

7.7          Choice of Law; Consent to Personal Jurisdiction.  All questions concerning the construction, validity and interpretation of this Agreement will be governed by the law of the State of North Carolina, without regard to its rules of conflicts or choice of laws. Executive hereby expressly consents to the personal jurisdiction and venue of the state and federal courts located in North Carolina for any lawsuit filed there against me by Company arising from or related to this Agreement.

 

7.8          Counterparts.  This Agreement may be executed in separate counterparts, any one of which need not contain signatures of more than one party, but all of which taken together will constitute one and the same Agreement. Delivery of an executed counterpart of this Agreement by facsimile, including, by facsimile transmission or by electronic delivery in portable document format (“.pdf”), tagged image file format (“.tiff”) or by DocuSign® or similar electronic signature exchange platform, shall be equally effective as delivery of a manually executed counterpart thereof.

 

[Signature Page follows]

 

 

 

 

IN WITNESS WHEREOF, the parties have executed this Employment Agreement on the day and year first written above.

 

  COMPANY:
   
  FENNEC PHARMACEUTICALS, INC.
   
     
  By:                                     
  Name: /s/ Khalid Islam
  Title: Chair
   
  EMPLOYEE:
   
   
  /s/ Jeff Hackman

 

 

 

EX-99.1 4 tm2421051d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

 

 

Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director

 

~ Accomplished Industry Leader Brings Extensive Commercialization and Oncology Expertise ~

 

~ Assumes Leadership Role at Critical Time to Expand Use of PEDMARK®, the First and Only Approved Treatment to Reduce the Risk of Cisplatin-Induced Ototoxicity ~

 

RESEARCH TRIANGLE PARK, N.C., August 5, 2024 – Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced the appointment of Mr. Jeff Hackman as its Chief Executive Officer (CEO) and a member of the Board of Directors, effective on or about August 16, 2024. Jeff will guide Fennec’s strategic direction for operational success in the expansion of PEDMARK® use in community oncology and the adolescent and young adult (AYA) population.

 

“Jeff’s appointment comes at a pivotal time for Fennec as we continue to advance PEDMARK®, the first and only therapy approved in the U.S. and Europe to reduce the risk of permanent damage from cisplatin-induced ototoxicity in pediatric cancer patients,” said Dr. Khalid Islam, Chairman of Fennec Pharmaceuticals. “We are confident that Jeff’s deep expertise in the commercialization of new therapies across multiple oncology indications, and extensive experience leading organizational growth and transformation, will bring tremendous value to Fennec.”

 

Jeff brings to Fennec more than 30 years of commercial leadership experience, including oversight of more than 10 product launches across a wide range of therapeutic areas and markets. His tenure in oncology spans the last 12 years across Sigma Tau, Baxalta, Shire, and EUSA Pharma, where he was responsible for the U.S. commercial organizations and managing the company’s product portfolio in multiple franchises, which generated billions in revenues over the years. More specifically, Jeff has successfully commercialized products that are specifically relevant to the PEDMARK® markets, including the outpatient oncology community and the AYA population.

 

“I am excited to lead Fennec and look forward to working with management and the Board of Directors to bring this much-needed treatment to oncology patients,” said Jeffrey S. Hackman, incoming chief executive officer of Fennec Pharmaceuticals.

 

Rosty Raykov, who has served as Fennec’s CEO since 2009, will remain a member of the Board of Directors. “Rosty’s unwavering commitment and leadership since 2009 has been critical to Fennec in bringing a much-needed therapy to the oncology population at risk of irreversible hearing loss, which can have a profound lifelong impact on patients,” said Khalid Islam.

 

 

 

 

About Fennec Pharmaceuticals

 

Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK® and Pedmarqsi® to reduce the risk of cisplatin-induced ototoxicity in pediatric patients. Further, PEDMARK received FDA approval in September 2022, and Pedmarqsi received European Commission Marketing Authorization in June 2023 and U.K. approval in October 2023. PEDMARK has received Orphan Drug Exclusivity in the U.S. for seven years of market protection and Pedmarqsi has received Pediatric Use Marketing Authorization in Europe, which includes eight years plus two years of data and market protection. Fennec has a license agreement with Oregon Health and Science University (OHSU) for exclusive worldwide license rights to intellectual property directed to sodium thiosulfate and its use for chemoprotection, including the reduction of risk of ototoxicity induced by platinum chemotherapy, in humans. For more information, please visit www.fennecpharma.com.

 

For further information, please contact:

 

Investors:

Robert Andrade

Chief Financial Officer

Fennec Pharmaceuticals Inc.

+1 919-246-5299

 

Corporate and Media:

Lindsay Rocco

Elixir Health Public Relations

+1 862-596-1304

lrocco@elixirhealthpr.com

 

 

 

EX-101.SCH 5 fencf-20240805.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 6 fencf-20240805_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 fencf-20240805_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 8 tm2421051d1_ex99-1img001.jpg GRAPHIC begin 644 tm2421051d1_ex99-1img001.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBHYYXK M:!YYG"1H-S,>PI-I*[&DV[(AU#4(-,LGNKAL(O0#JQ[ >]5/#]Q<7VGF^N>& MN'+*@/"(. !^6?QK@]:U>?7+\$ K$#M@C],\9/N:]+L[=;2RAMU^[$@0?@*\ M[#8EXFO)Q^&/XM]3T,1AEAJ$5+XI?@ET)J***](\X**** "BBB@ HHHH *** M* "BBB@ Z#)KSKQ1KYU.X^RV[?Z)$W4?\M&]?H.WYUL>,-<,$9TRV?$D@S,P M/W5/;ZG^7UKAJ^?S7&W?L(?/_+_,]_*\%9>WG\O\S7\,VOVOQ!:J1E8R96_X M#T_7%>GUQG@2U_X^[PCTB4_J?Z5V==N4TN3#\W=W_0X\UJ\^(Y>P4445Z9Y@ M4444 %%%% !1110 4444 %%%% 'D6H&8ZE=&X.9O-;?]#!E#*00>A%>5Z_.MSK=TR8\M&\I .F M%X_H:M:'JEUHTD$S/FPF\''J<=01^M>Q0S.-.7L7'W5I?\+GD5\ME4C[ M92]YZV_&QW%_K(LKZ*SCLKJ[N)(FE"P!.%! ).YAW85%!KZW-Y+!'IUX5AD\ MN64^6%1MH8@_-GC(Z TRXTC2]=U*&_F-O>110-$(BH=&&@ MUJXOXY;,B:8R$O9YE0%0I59-W P/3N:^BBZ3C>_0^9XKMXC-9-:R+L MRK,0H\S&>#A #ZX'I5VH7W,[XFVR+[^(%A@5Y].O8I9)!%# 0C/,Q!/R[6(X M )))&*M1ZGOT][J2SN8&1MAAE4!\Y XYP1SUSBLN/PS-%!'Y-Q9VUQ!/Y\#V MMD(T!VE6#KN.X$''4&M(6%S-ILEM?W@GDD;+.D6P 9!V@ YQQUSFHDJ?3]32 M#J]?T)8]05KA;>2&2*8G[K8/&"(^4A1&+E67=N)&,G/I4::-$LF1(RQAG9(XOD"[CST^G\_6I]PO\ M>$T^H>3+(JV\LJQ('=T*X .?4\]*8=8M1!=2GS,6WWEV\OD9&T=\]![U!_8, M+1L'D+,$5(G89*A22N?[W4 YZX]ZL'2XG$C28:5BY1\?C M*4IK=%K4+&+4;"6TF^[(N,_W3V/X&O/]'M9--U>\EN5 ;3H7UAW7E\ZQG:.65+M76\?Q[?B>K@*\E>@]I?AW_ M //222:N6VDZA>+OM[*:13_$%P#^)KMM%\)6UBJS7@6XN>N",HGT'? MZFNDZ5Y^'R>4ES5G;R._$9O&+Y:2OYGGFG>$=6>X5Y#]C3/S.'^?'MCO7H2C M:H7).!CDTM%>QA<'3PR:AU/)Q.+J8EISZ!11174 XML 10 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Cover
Aug. 05, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 05, 2024
Entity File Number 001-32295
Entity Registrant Name FENNEC PHARMACEUTICALS INC.
Entity Central Index Key 0001211583
Entity Tax Identification Number 20-0442384
Entity Incorporation, State or Country Code A1
Entity Address, Address Line One PO Box 13628
Entity Address, Address Line Two 68 TW Alexander Drive
Entity Address, City or Town Research Triangle Park
Entity Address, State or Province NC
Entity Address, Postal Zip Code 27709
City Area Code 919
Local Phone Number 636-4530
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common shares, no par value
Trading Symbol FENC
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://adherex.com/role/Cover Cover Cover 1 false false All Reports Book All Reports fencf-20240805.xsd fencf-20240805_lab.xml fencf-20240805_pre.xml tm2421051d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2421051d1_8k.htm": { "nsprefix": "fencf", "nsuri": "http://adherex.com/20240805", "dts": { "schema": { "local": [ "fencf-20240805.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "fencf-20240805_lab.xml" ] }, "presentationLink": { "local": [ "fencf-20240805_pre.xml" ] }, "inline": { "local": [ "tm2421051d1_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://adherex.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-08-05", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2421051d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-08-05", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2421051d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 18 0001104659-24-086369-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-086369-xbrl.zip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end XML 19 tm2421051d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001211583 2024-08-05 2024-08-05 iso4217:USD shares iso4217:USD shares false 0001211583 8-K 2024-08-05 FENNEC PHARMACEUTICALS INC. 001-32295 A1 20-0442384 PO Box 13628 68 TW Alexander Drive Research Triangle Park NC 27709 919 636-4530 false false false false Common shares, no par value FENC NASDAQ false